Literature DB >> 19635525

Catalpol ameliorates beta amyloid-induced degeneration of cholinergic neurons by elevating brain-derived neurotrophic factors.

Z Wang1, Q Liu, R Zhang, S Liu, Z Xia, Y Hu.   

Abstract

The purpose of this work is to study the effect of catalpol, an iridoid from Rehmannia glutinosa on neurodegenerative changes induced by beta-amyloid peptide Abeta(25-35) or Abeta(25-35)+ibotenic acid and the underlying mechanism. Results showed that catalpol significantly improved the memory deficits in the neurodegenerative mouse model produced by injection of Abeta(25-35)+ibotenic acid to the nucleus magnocellularis basalis, yet it is neither a cholinesterase inhibitor nor a muscarinic (M) receptor agonist. Instead, the choline acetyl transferase (ChAT) activity and the M receptor density in brain were significantly decreased in the model mice and catalpol could significantly elevate their levels. Furthermore, the brain-derived neurotrophic factor (BDNF) content in brain was significantly decreased in the model mice and catalpol elevated it to normal level (83%+/-3% and 102%+/-2% of normal respectively). There is a significant positive correlation between BDNF content and memory. Primary culture of forebrain neurons revealed that aggregated Abeta(25-35) induced significant decrease of ChAT positive neuron number, neurite outgrowth length, and M receptor density, while catalpol added to the culture medium 2 h prior to Abeta addition showed significant dose dependent protective effect. Notably, 24 h and 48 h after the addition of Abeta to the cultured cells, the BDNF mRNA level in the neurons decreased to 76%+/-7% and 66%+/-3% of control without catalpol treatment, but became 128%+/-17% and 131%+/-23% of control with catalpol treatment. When the action of BDNF was inhibited by k252a in the cultured neurons, the protective effect of catalpol was completely (neurite outgrowth length) or partially (ChAT positive neuron number and the M receptor density) abolished. Taken together, catalpol improves memory and protects the forebrain neurons from neurodegeneration through increasing BDNF expression. Whether catalpol could reverse the neurodegenerative changes already present before its application remains to be further studied.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19635525     DOI: 10.1016/j.neuroscience.2009.07.041

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  18 in total

1.  Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats.

Authors:  Yu-Fang Cheng; Chuang Wang; Huan-Bing Lin; Yun-Feng Li; Ying Huang; Jiang-Ping Xu; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2010-07-17       Impact factor: 4.530

2.  Separation of catalpol from Rehmannia glutinosa Libosch. by high-speed countercurrent chromatography.

Authors:  Shengqiang Tong; Lin Chen; Qing Zhang; Jian Liu; Jizhong Yan; Yoichiro Ito
Journal:  J Chromatogr Sci       Date:  2014-09-11       Impact factor: 1.618

Review 3.  Neurotrophin strategies for neuroprotection: are they sufficient?

Authors:  Joseph P Steiner; Avindra Nath
Journal:  J Neuroimmune Pharmacol       Date:  2014-03-08       Impact factor: 4.147

Review 4.  Neurotrophic function of phytochemicals for neuroprotection in aging and neurodegenerative disorders: modulation of intracellular signaling and gene expression.

Authors:  Makoto Naoi; Keiko Inaba-Hasegawa; Masayo Shamoto-Nagai; Wakako Maruyama
Journal:  J Neural Transm (Vienna)       Date:  2017-10-13       Impact factor: 3.575

5.  Ethanol extract of Rehmannia glutinosa exerts antidepressant-like effects on a rat chronic unpredictable mild stress model by involving monoamines and BDNF.

Authors:  Jun-Ming Wang; Li-Xin Pei; Yue-Yue Zhang; Yong-Xian Cheng; Chun-Ling Niu; Ying Cui; Wei-Sheng Feng; Gui-Fang Wang
Journal:  Metab Brain Dis       Date:  2018-02-22       Impact factor: 3.584

Review 6.  A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.

Authors:  Shams Tabrez; Nasimudeen R Jabir; Shazi Shakil; Nigel H Greig; Qamre Alam; Adel M Abuzenadah; Ghazi A Damanhouri; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-06-01       Impact factor: 4.388

Review 7.  Effects of Catalpol on Alzheimer's Disease and Its Mechanisms.

Authors:  Huize Chen; Chujun Deng; Zeyu Meng; Shengxi Meng
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-30       Impact factor: 2.650

8.  Catalpol improves impaired neurovascular unit in ischemic stroke rats via enhancing VEGF-PI3K/AKT and VEGF-MEK1/2/ERK1/2 signaling.

Authors:  Hong-Jin Wang; Hai-Feng Ran; Yue Yin; Xiao-Gang Xu; Bao-Xiang Jiang; Shi-Qi Yu; Yi-Jin Chen; Hui-Jing Ren; Shan Feng; Ji-Fen Zhang; Yi Chen; Qiang Xue; Xiao-Yu Xu
Journal:  Acta Pharmacol Sin       Date:  2021-11-18       Impact factor: 7.169

9.  PMC-12, a Prescription of Traditional Korean Medicine, Improves Amyloid β-Induced Cognitive Deficits through Modulation of Neuroinflammation.

Authors:  Min Young Park; Yeon Suk Jung; Jung Hwa Park; Young Whan Choi; Jaewon Lee; Cheol Min Kim; Jin Ung Baek; Byung Tae Choi; Hwa Kyoung Shin
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-07       Impact factor: 2.629

Review 10.  The next step of neurogenesis in the context of Alzheimer's disease.

Authors:  Hamid Reza Moradi; Vahid Hajali; Zabihollah Khaksar; Farzaneh Vafaee; Fatemeh Forouzanfar; Sajad Sahab Negah
Journal:  Mol Biol Rep       Date:  2021-07-07       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.